Long Term, Multicenter, Single-arm, Open-label Extension Study of the MERIT-1 Study, to Assess the Safety, Tolerability and Efficacy of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

Trial Profile

Long Term, Multicenter, Single-arm, Open-label Extension Study of the MERIT-1 Study, to Assess the Safety, Tolerability and Efficacy of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Nov 2017

At a glance

  • Drugs Macitentan (Primary)
  • Indications Pulmonary hypertension
  • Focus Adverse reactions
  • Acronyms MERIT-2
  • Sponsors Actelion Pharmaceuticals
  • Most Recent Events

    • 21 Jun 2017 Planned End Date changed from 1 Jun 2018 to 28 Sep 2018.
    • 21 Jun 2017 Planned primary completion date changed from 1 Jun 2018 to 28 Sep 2018.
    • 21 Oct 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top